Abstract

Metastasis to bone is common in lung, kidney, breast and prostate cancers. However, prostate cancer is unique in that bone is often the only clinically detectable site of metastasis, and the resulting tumours tend to be osteoblastic (bone forming) rather than osteolytic (bone lysing). The interaction between host cells and metastatic cancer cells is an important component of organ-specific cancer progression. How can this knowledge lead to the development of more effective therapies?

Author affiliations

1. Department of Genitourinary Oncology, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.
2. Department of Molecular Pathology, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

Correspondence to: Christopher J. Logothetis¹ Email: clogothe@mdanderson.org

Correspondence to: Sue-Hwa Lin² Email: slin@mdanderson.org

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.